Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 9, 2019updated 23 Dec 2019 9:31am

Opthea reports positive data from Phase IIb trial in wet AMD

Australian biopharmaceutical firm Opthea has reported positive data from the Phase IIb clinical trial of OPT-302 in combination with ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration (AMD).

Australian biopharmaceutical firm Opthea has reported positive data from the Phase IIb clinical trial of OPT-302 in combination with ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration (AMD).

The data has been presented at the European Society of Retina Specialists EURETINA 2019 Congress held in Paris.

It showed that the trial met its primary endpoint, showing superior vision gains with the combination treatment compared to sham plus ranibizumab, which was considered as control.

According to findings from additional analysis, the combination also led to a decrease in CST, sub-retinal fluid, intra-retinal cysts, total lesion area and choroidal neovascularisation (CNV) area.

Opthea CEO and managing director Dr Megan Baldwin said: “Together with the previously reported superiority in visual acuity gains, the further data analyses support the primary outcome of the study and demonstrate that OPT-302 has direct mechanistic effects on wet AMD lesion pathology.”

OPT-302 is a vascular endothelial growth factor receptor 3 (VEGFR-3) molecule designed to inhibit the activity of VEGF-C and VEGF-D proteins implicated in various retinal disorders.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The therapeutic is being developed in conjunction with VEGF-A inhibitors to facilitate the enhanced inhibition of disease pathways for better vision outcomes.

In combination with 0.5mg ranibizumab, 2mg and 0.5mg OPT-302 was assessed in 366 treatment-naïve patients who participated in the multi-centre, prospective, double-masked Phase IIb trial. 

The therapy was given every four weeks for 24 weeks via intravitreal administration.

The safety profile of OPT-302 was observed to be similar to that of the control arm.  The investigational combination was well tolerated without any safety concerns, Opthea noted.

Two ocular serious adverse events (SAEs) were reported in patients treated with 0.5mg OPT-302 plus ranibizumab. One adverse event was associated with trial discontinuation.

The company added that two patient deaths that occurred in the control group were not related to the study drugs.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU